Antivenom is expensive because of a perfect storm of factors: a labor-intensive biological manufacturing process, a small market with limited competition, and a treatment protocol that often requires many vials per patient. A single rattlesnake bite in the U.S. typically requires 15 to 20 vials of antivenom, with wholesale prices ranging from roughly $1,584 to $3,838 per vial depending on the product. That means the antivenom alone can cost $25,000 to $75,000 before hospital fees even enter the picture.
How Antivenom Is Made
Unlike most drugs, antivenom can’t be synthesized in a lab from a chemical formula. It’s a biological product, meaning it has to be grown inside living organisms. The process starts with venom extraction, where trained handlers physically milk venomous snakes to collect tiny quantities of venom. A single eastern brown snake, for example, yields only about 40 to 144 milligrams of venom per milking depending on the population, and that raw venom is the essential starting ingredient.
That venom is then injected in small, increasing doses into donor animals, usually horses or sheep, over a period of months. The animal’s immune system gradually builds up antibodies against the venom’s toxins. Once antibody levels are high enough, blood is drawn from the animal and the plasma is harvested. The antibodies are then purified and processed into a form that can be safely injected into humans. Every step, from snake milking to animal immunization to antibody purification, requires specialized facilities, skilled personnel, and strict quality controls. The entire cycle from venom collection to finished product takes months, and scaling up production isn’t as simple as building a bigger factory.
A Small Market With Few Players
Snakebites are relatively rare in the United States, with roughly 7,000 to 8,000 venomous bites reported each year. That’s a tiny market compared to drugs for common conditions like high blood pressure or diabetes, which serve tens of millions of patients. Developing and manufacturing antivenom requires enormous upfront investment, but the customer base is small and unpredictable. Hospitals in regions with few venomous snakes may stock antivenom that expires before it’s ever used.
This small market discourages new companies from entering the space. The major antivenom products available in the U.S. come from a handful of manufacturers, including companies like CSL, Pfizer, and Merck. With so few competitors, there’s little downward pressure on pricing. The FDA approval process for biological products is also rigorous and expensive, adding another barrier that keeps potential competitors on the sidelines. The result is something close to a monopoly for certain antivenom types, which gives existing manufacturers significant pricing power.
Multiple Vials Per Treatment
The cost per vial is only part of the equation. What makes the total bill staggering is how many vials a single patient needs. The average rattlesnake bite in the U.S. requires about 15 vials of antivenom, with a range of 5 to 40 vials depending on the severity of the envenomation. Treatment starts with an initial dose to control symptoms, followed by additional doses over the next several hours to prevent venom that’s still circulating from causing further damage.
At current wholesale prices, the two main antivenom products in the U.S. sit at very different price points. The newer product costs around $1,584 per vial at wholesale, while the older, more established product runs approximately $3,838 per vial. A 2025 study in the Journal of Medical Toxicology found that Medicare reimburses these products at $433 and $2,078 per vial, respectively, highlighting the gap between what manufacturers charge and what insurers pay. For patients, the final hospital bill often includes not just the antivenom itself but also emergency department fees, monitoring, and lab work that can push the total into six figures.
Two Types of Antivenom, Two Price Tags
The U.S. market currently has two main antivenom products for pit viper bites (rattlesnakes, copperheads, and cottonmouths). They use different antibody technologies. One is made from smaller antibody fragments called Fab, and the other uses slightly larger fragments called F(ab’)2. The Fab product has been on the market longer and carries the higher per-vial price tag, but the F(ab’)2 product may require fewer total vials per treatment course. When researchers compared total treatment costs rather than per-vial costs, the price difference between the two products narrowed considerably. Still, both remain expensive by any standard.
Hospital Markups Add Another Layer
The price a hospital pays for antivenom is not the price that shows up on your bill. Hospitals apply markups to cover their own costs: stocking a product that may expire on the shelf, staffing an emergency department around the clock, and providing the monitoring that antivenom administration requires. Antivenom must be given under medical supervision because allergic reactions, including a serious immune response called serum sickness, can occur. The gap between the wholesale acquisition cost and the amount billed to patients or insurers is often substantial, sometimes doubling or tripling the base price of the medication.
Storage and Waste Drive Costs Up
Antivenom has a limited shelf life and typically requires refrigeration. Hospitals in snake-prone regions need to keep it on hand year-round, even though bites are seasonal and unpredictable. A hospital might stock 20 or 30 vials and use only a fraction before expiration dates pass. Those expired vials represent a complete financial loss, and the cost of that waste gets built into the price charged for the vials that do get used. Rural and critical-access hospitals face this problem most acutely: they’re often in areas with the highest snakebite risk but the lowest patient volume to absorb the cost.
Why It Costs Less in Other Countries
Antivenom prices vary dramatically around the world. Globally, treatment costs range from as low as $13 to over $1,120 per course, according to research published in Frontiers in Bioengineering and Biotechnology. Countries like Mexico and Brazil produce antivenom through government-funded laboratories, which removes the profit motive and dramatically reduces the final price. In the U.S., antivenom is produced and sold by private companies operating in a market-based system with limited price regulation. The same economic dynamics that make many American pharmaceuticals more expensive than their international equivalents apply with particular force to antivenom, where the small market amplifies every cost along the supply chain.
New Technologies Could Lower Prices
Researchers are working on next-generation antivenoms that bypass the need for animal immunization entirely. These products use lab-engineered antibodies, sometimes called monoclonal antibodies or nanobodies, that can be produced in cell cultures rather than in horses or sheep. Early cost analyses suggest that cocktails of these engineered antibodies could be manufactured at prices comparable to or lower than current animal-derived antivenoms. Smaller antibody formats, like nanobodies and other engineered protein fragments, could push costs down even further because they require less raw material per dose and are simpler to produce at scale. These products are still in development, but they represent the most promising path toward making antivenom more affordable and more widely available.